傳奇生物公司-ADR

LEGN is the Nasdaq ticker for Legend Biotech Corporation, a clinical-stage biotechnology company. The company focuses on discovering and developing novel cell therapies for oncology and other serious diseases. Its lead product candidate is ciltacabtagene autoleucel (cilta-cel), developed in collaboration with Johnson & Johnson. LEGN stock allows investors to participate in the company's potential growth, but it carries the risks typical of clinical-stage biotech firms. For current details, refer to the latest LEGN data on this page.

The latest price of LEGN stock is available on this page, updated in real time. Stock prices fluctuate throughout the trading day based on supply and demand, news, and broader market conditions. For the most accurate and current quote, please check the live data displayed above. Historical prices and charts can also provide context on how the stock has traded over time.

Because LEGN is a clinical-stage biotech company, traditional valuation metrics like the P/E ratio may not be meaningful if the company is not yet profitable. Investors often look at price-to-sales, price-to-book, cash runway, and pipeline progress. Comparing LEGN to similar biotech firms and assessing the potential of its drug candidates can also help. For current valuation multiples, please refer to the latest data on this page.

To buy LEGN stock, you need a brokerage account that offers access to U.S. markets. Once your account is funded, you can place a buy order for LEGN shares through your broker's platform. The stock trades on the Nasdaq under the ticker LEGN. Trading fees, commissions, and minimum purchase requirements vary by broker. Fractional shares may be available depending on your brokerage. Always confirm the latest price and order details before executing a trade.

LEGN carries risks typical of clinical-stage biotech companies, including clinical trial failures, regulatory delays, and competition. As a foreign private issuer, it may have different disclosure requirements. The company may need additional capital, potentially diluting shareholders. Market sentiment toward biotech and broader economic conditions can also influence the stock. For a comprehensive risk assessment, review Legend Biotech's SEC filings and the latest LEGN data on this page.

To analyze LEGN's financial performance, start with its income statement, balance sheet, and cash flow statement. Key metrics for a clinical-stage biotech include cash and equivalents, operating expenses, net loss, and research and development spending. Revenue may be limited or absent until products are approved. Comparing these metrics over time and against peers can provide insights. For the latest financials, refer to the company's quarterly and annual reports.